Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis
详细信息 查看全文
- 作者：Yuji Kasukawa (1)
Naohisa Miyakoshi (1)
Toshihito Ebina (2)
Toshiaki Aizawa (2)
Michio Hongo (1)
Koji Nozaka (1)
Yoshinori Ishikawa (1)
Hidetomo Saito (1)
Shuichi Chida (1)
Yoichi Shimada (1) - 关键词：Risedronate ; Vitamin K2 ; Undercarboxylated osteocalcin (ucOC) ; Osteocalcin ; Vertebral fracture
- 刊名：Journal of Bone and Mineral Metabolism
- 出版年：2014
- 出版时间：May 2014
- 年：2014
- 卷：32
- 期：3
- 页码：290-297
- 全文大小：
- 参考文献：1. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353:878-82 CrossRef
2. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513-21 CrossRef
3. Lee YK, Jang S, Jang S, Lee HJ, Park C, Ha YC, Kim DY (2012) Mortality after vertebral fracture in Korea. Analysis of the National Claim Registry. Osteoporos Int 23:1859-865 CrossRef
4. Kishimoto H, Fukunaga M, Kushida K, Shiraki M, Itabashi A, Nawata H, Nakamura T, Ohta H, Takaoka K, Ohashi Y (2006) Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5 mg once-daily dosage regimen. J Bone Miner Metab 24:405-13 CrossRef
5. Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G (2002) Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23:517-23 CrossRef
6. Bolland MJ, Grey AB, Gamble GD, Reid IR (2010) Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 95:1174-181 CrossRef
7. Center JR, Bliuc D, Nguyen ND, Nguyen TV, Eisman JA (2011) Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endoclinol Metab 96:1006-014 CrossRef
8. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282:1344-352 CrossRef
9. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254-259 CrossRef
10. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton LJ 3rd, O’Neill T, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185-194 CrossRef
11. Vestergaard P, Mosekilde L (2003) Fracture risk associated with smoking: a meta-analysis. J Intern Med 254:572-83 CrossRef
12. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721-39 CrossRef
13. Kanis JA, Johansson H, Oden A, Johnell O, De Laet C, Melton LJ III, Tenenhouse A, Reeve J, Silman AJ, Pols HA, Eisman JA, McCloskey EV, Mellstrom D (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893-99 CrossRef
14. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A (2007) Use of calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50?years and older: a meta-analysis. Lancet 370:657-66 CrossRef
15. Cockayne S, Adamson J, Lanham-New S, Shearer MJ, Gilbody S, Torgerson DJ (2006) Vitamin K and the prevention of fractures: systemic review and meta-analysis of randomized controlled trials. Arch Intern Med 166:1256-261 CrossRef
16. Tsugawa N, Shiraki M, Suhara Y, Kamao M, Ozaki R, Tanaka K, Okano T (2008) Low plasma phylloquinone concentration is associated with high incidence of vertebral fracture in Japanese women. J Bone Miner Metab 26:79-5 CrossRef
17. Kaneki M, Hedges SJ, Hosoi T, Fujiwara S, Lyons A, Crean SJ, Ishida N, Nakagawa M, Takechi M, Sano Y, Mizuno Y, Hoshino S, Miyao M, Inoue S, Horiki K, Shiraki M, Ouchi Y, Orimo H (2001) Japanese fermented soybean food as the major determinant of the large geographic difference in circulating levels of vitamin K2: possible implications for hip-fracture risk. Nutrition 17:315-21 CrossRef
18. Hauschka PV, Lian JB, Cole DE, Gundberg CM (1989) Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 69:990-047
19. Suttie JW (1985) Vitamin K-dependent carboxylase. Annu Rev Biochem 54:459-77 CrossRef
20. Miki T, Nakatsuka K, Naka H, Kitatani K, Saito S, Masaki H, Tomiyoshi Y, Morii H, Nishizawa Y (2003) Vitamin K (menaquinone 4) reduces serum undercarboxylated osteocalcin level as early as 2?weeks in elderly women with established osteoporosis. J Bone Miner Metab 21:161-65 CrossRef
21. Ozuru R, Sugimoto T, Yamaguchi T, Chihara K (2002) Time dependent effects of vitamin K2 (menatetrenone) on bone metabolism in postmenopausal women. Endocr J 49:363-70 CrossRef
22. Tsugawa N, Shiraki M, Uenishi K, Ishida H, Minekami T, Kawamoto S, Mouri K, Okano T (2011) Association of vitamin K status with clinical fracture in elderly people. Osteoporos Jpn 19:244-45 (In Japanese)
23. Shiraki M, Aoki C, Yamazaki N, Ito Y, Tsugawa N, Suhara Y, Okano T (2007) Clinical assessment of undercarboxylated osteocalcin measurement in serum using an electrochemiluminescence immunoassay: establishments of cut-off values to determine vitamin K insufficiency in bone and to predict fracture leading to clinical use of vitamin K2. Iyaku Yakugaku 57:537-46 (In Japanese)
24. Aonuma H, Miyakoshi N, Hongo M, Kasukawa Y, Shimada Y (2009) Low serum levels of undercarboxylated osteocalcin in postmenopausal osteoporotic women receiving an inhibitor of bone resorption. Tohoku J Exp Med 218:201-05 CrossRef
25. Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC II (1996) Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 101:488-01 CrossRef
26. Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Kaneda K, Minaguchi H, Inoue T, Tomita A, Nagata Y, Nakashima M, Orimo H (1998) A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. The Alendronate Research Group. Endocr J 45:191-01 CrossRef
27. Hirao M, Hashimoto J, Ando W, Ono T, Yoshikawa H (2008) Response of serum carboxylated and undercarboxylated osteocalcin to alendronate monotherapy and combined therapy with vitamin K2 in postmenopausal women. J Bone Miner Metab 26:260-64 CrossRef
28. Shiraki M, Yamazaki Y, Shiraki Y, Hosoi T, Tsugawa N, Okano T (2010) High level of serum undercarboxylated osteocalcin in patients with incident fractures during bisphosphonate treatment. J Bone Miner Metab 28:578-84 CrossRef
29. Uenishi K, Ishida H, Kamao M, Tsugawa N, Okano T, Shiraki M (2011) Development and evaluation of simple vitamin K intake questionnaire. Osteoporos Jpn 19:513-18 (In Japanese)
30. Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137-148 CrossRef
31. Fukunaga M, Nakamura T, Shiraki M, Kuroda T, Ohta H, Hosoi T, Orimo H (2004) Absolute height reduction and percent height ratio of the vertebral body in incident fracture in Japanese women. J Bone Miner Metab 22:104-10 CrossRef
32. Murata K, Yano E (2002) Medical statistical for evidence-based medicine with SPBS user’s guide. Nankodo, Tokyo
33. Vermeer C (1990) Gamma-carboxyglutamate-containing proteins and the vitamin K-dependent carboxylase. Biochem J 266:625-36
34. Hozuki T, Imai T, Tsuda E, Matsumura A, Yamamoto D, Toyoshima T, Suzuki S, Yamauchi R, Hayashi T, Hisahara S, Shimohama S (2010) Response of serum carboxylated and undercarboxylated osteocalcin to risedronate monotherapy and combined therapy with vitamin K2 in corticosteroid-treated patients: a pilot study. Intern Med 49:371-76 CrossRef
35. Iwamoto J, Takeda T, Ichihara S (2003) Combined treatment with vitamin K2 and bisphosphonate in postmenopausal women with osteoporosis. Yonsei Med J 44:751-56
36. Kasukawa Y, Miyakoshi N, Hongo M, Ishikawa Y, Noguchi H, Kamo K, Sasaki H, Murata K, Shimada Y (2010) Relationships between falls, spinal curvature, spinal mobility and back extensor strength in elderly people. J Bone Miner Metab 28:82-7 CrossRef
37. Horiuchi T, Kazama H, Araki A, Inoue J, Hosoi T, Onouchi T, Mizuno S, Ito H, Orimo H (2004) Impaired gamma carboxylation of osteocalcin in elderly women with type II diabetes mellitus: relationship between increase in undercarboxylated osteocalcin levels and low bone mineral density. J Bone Miner Metab 22:236-40 CrossRef
38. Tanaka I, Hayakawa K, Oshima H (2009) Drug compliance of bisphosphonate in Japan: cohort study of bisphosphonate in a private clinic. Osteoporos Jpn 17:252-55 (In Japanese) - 作者单位：Yuji Kasukawa (1)
Naohisa Miyakoshi (1)
Toshihito Ebina (2)
Toshiaki Aizawa (2)
Michio Hongo (1)
Koji Nozaka (1)
Yoshinori Ishikawa (1)
Hidetomo Saito (1)
Shuichi Chida (1)
Yoichi Shimada (1)
1. Department of Orthopedic Surgery, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan
2. Department of Orthopedic Surgery, Kakunodate General Hospital, Senboku, 010-0394, Japan - ISSN：1435-5604
文摘
Risedronate decreases osteoporotic fracture incidence; however, its effects remain unclear in elderly osteoporotic patients. Vitamin K mediates carboxylation of osteocalcin (OC), and high undercarboxylated osteocalcin (ucOC) levels indicate vitamin K deficiency and increased osteoporotic fracture risk. We aimed to evaluate the effects of risedronate alone or combined with vitamin K2 on serum ucOC, OC, and incidence of vertebral fractures in elderly osteoporotic patients. A total of 101 women with postmenopausal osteoporosis aged >60?years were randomly stratified into two groups—R group (n?=?51), treated with risedronate alone; and R?+?K group (n?=?50), treated with risedronate and vitamin K2. Serum ucOC, OC and incidence of vertebral fractures were evaluated before treatment and at 6 and 12?months post-treatment. Decreased ucOC rates at 6 and 12?months were not significant between groups. However, at 6 and 12?months, decreased OC rates in the R group (p?<?0.01 and 0.05, respectively) were significantly higher than in the R?+?K group, and ucOC/OC change rates in the R group (p?<?0.05 and 0.001, respectively) were significantly lower than in the R?+?K group. Vertebral fracture incidence was not significantly different between the groups at 6 and 12?months. ucOC levels in patients with incident vertebral fractures were significantly higher than in patients without incident vertebral fractures in the R group at 6?months (p?<?0.05). Although no significant difference was observed for ucOC decrease rate and incidence of vertebral fractures between treatments, ucOC levels in patients with incident vertebral fractures were significantly greater than in patients without when using risedronate alone.